WO2000049038A2 - Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung - Google Patents
Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung Download PDFInfo
- Publication number
- WO2000049038A2 WO2000049038A2 PCT/DE2000/000525 DE0000525W WO0049038A2 WO 2000049038 A2 WO2000049038 A2 WO 2000049038A2 DE 0000525 W DE0000525 W DE 0000525W WO 0049038 A2 WO0049038 A2 WO 0049038A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vpr
- glu
- arg
- leu
- ile
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the invention relates to synthetic peptides of the regulatory virus protein R (Vpr) of the human immunodeficiency virus type 1 (HIV-1). in particular the chemical total synthesis of the 96 amino acid long Vpr protein (sVprl-96) and its sequences.
- Vpr regulatory virus protein
- sVprl-96 96 amino acid long Vpr protein
- synthetic Vpr peptides they are used in biological assays, in the analysis of the molecular structure 10 and the physicochemical properties of Vpr and its domains, and for the generation of antibodies against Vpr peptide sequences.
- Vpr cation-selective ion channel
- Vpr A recombinant Vpr fusion protein forms oligomeric structures with molecular weights of> 100 kDa (Zhao et al.,
- Vpr studies on the molecular structure of Vpr were carried out by two groups using secondary structure analyzes on short Vpr peptides: NMR studies on overlapping peptides in aqueous trifluoroethanol (TFE) and alpha-helical regions identified in sodium dodecyl sulfate (SDS) micelles in the Vpr
- Vpr peptide does not give any information about the purity or the physicochemical properties of the Vpr peptide. It is only shown by means of the Far-West emblot technique that SDS-denatured Vpr peptide interacts with the viral nucleoprotein NCp7 of the same HIV-1 isolate. This finding of the NCp7-Vpr interaction has so far not been confirmed by any of the numerous other groups researching in the Vpr field. A major disadvantage of this Vpr synthesis is the fact that none of the biological activities described has been shown by the authors for this peptide. In particular, it is shown that this Vpr peptide does not bind to p6 G ⁇ , a widely accepted property of Vpr (Paxton et al.
- Vpr. Short, about 20 amino acid long peptides of the C-terminal region of Vpr. which contain the motif "HF / SRIG", have a concentration of 0.7 to 3 micro-M cytotoxic effects against various yeast strains, such as Saccharomyces cerevisiae. Candida albicans and Schizosaccharomyces pombe (Macreadie et al. 1996, 1997) triggers.
- Further studies showed that a C-terminal Vpr peptide (positions 71-82) membrane permeabilization.
- Recombinant Vpr of the isolate HIV-1 NL - 3 was expressed in insect cells after infection with recombinant baculoviruses (Levy et al. 1995). The purification of the product was carried out only by immunoaffinity chromatography on immobilized polyclonal antiserum which is directed against the N-terminal domain of Vpr. Cell culture supernatants were used for this, since recombinant Vpr is secreted non-specifically into the culture medium. Purification strategies for the production of large amounts of recombinant Vpr have not been described. In most cases, authors used Vpr-containing cell culture supernatants for biological tests. It was shown that recombinant Vpr activates virus replication in PBMC (peripheral blood mononuclear cells) and in various latently infected monocyte and T cell lines. The main disadvantages of this procedure are:
- Vpr Recombinant Vpr was mixed with detergents in the process of affinity purification, which made dialysis and renaturation necessary;
- Vpr The effect of recombinant Vpr in HIV-infected primary monocytes / macrophages has not been tested.
- Expression, purification and biochemical characterization of recombinant Vpr were first described in 1994 by Zhao and co-workers.
- a 25 amino acid sequence of the heterologous FLAG epitope was fused C-terminally in this method. Except for the oligomerization reported no biological activities of the recombinant product in this work.
- a major disadvantage of this method is the fact that Vpr is not expressed in its authentic sequence, but as a fusion protein.
- Vpr of the isolate HIV-1 H XB2 was expressed in E. coli as a GST-5 fusion protein (Piller et al, 1996). After affinity chromatography on glutathione agarose, Vpr was freed of the fusion portion by thrombin cleavage.
- a major disadvantage of this method is the fact that Vpr has a strong tendency to aggregate after cleavage and cannot be kept in aqueous solution. For example, Arunagiri and co-workers (1997) report that recombinant Vpr
- Patent application WO 95/26361 (Azad, A.A .. Macreadie, LG .. Arunagiri, C, 1995) describes biologically active peptide fragments of the Vpr protein of HIV;
- chimeric molecules are protected, consisting of Vpr from HIV-1 and Vpx from HIV-2, which can be specifically incorporated into HIV-1 / HIV-2 virus particles and disrupt the structural organization and functional integrity of virions there . However, they are excluded for use in gene therapy for HIV-1 / HIV-2 infections.
- WO 96/08970 Weiner, D.B .; Levy, D.N .; Refaeli, Y., 1996) describes methods for
- Vpr proteins 25 Inhibition of cell division and lymphocyte activation using Vpr proteins, fragments of Vpr or gene sequences of Vpr are described. The chemical synthesis of Vpr proteins plays no role in this.
- the object of the invention is to develop a synthesis route for Vpr peptides on a mg scale, to enable their purification and to make the end product available to the general public.
- the object was achieved according to the invention by providing the protein sVprl-96 and the peptides
- the C-terminal Vpr peptides were synthesized on a serine resin using a Perkin-Elmer synthesizer. All N-terminal peptides were synthesized on a polystyrene-polyoxyethylene carrier resin. The peptides were built up using FMOC (fluoromethyloxycarbonyl) strategy using protective groups. After the synthesis had ended, the protective groups were cleaved off using a cleavage mixture consisting of 95% trifluoroacetic acid, 3% triisopropylsilane and, depending on the peptide, 2 to 5% ethanedithiol. The resin was separated off, the reaction solution was concentrated and heptane was added.
- FMOC fluoromethyloxycarbonyl
- the sVpr peptides produced according to the invention after this purification procedure - in contrast to the recombinant or synthetic products described hitherto - are water-soluble and are not subject to protein aggregation even in high concentrations of up to mM solutions. It could be shown that the protein sVprl-96 assumes a folded structure, has biological activities comparable to viral Vpr and is immunologically reactive.
- Vpr protein corresponds to the amino acid sequence of the virus isolate HIV-KL-I-S.
- Vpr peptides are understood to mean the peptides produced by solid phase synthesis, which contain the authentic amino acid sequence of the native Vpr protein, such as that by the vpr gene of the molecular isolate HIV-1 NL . 3 is encoded.
- the essence of the invention lies in a combination of known features (starting materials, synthetic resins, synthesizers) and new solutions - the first-time chemical synthesis of these compounds, the synthetic strategy, the choice of specific protective groups, the trifluoroacetic acid-triisopropylsilane-ethanedithiol cleavage mixture according to the invention.
- the use of a certain solvent gradient (TFA-water: TFA-acetonitrile for cleaning - which mutually influence one another and, in their new overall effect, give an advantage in use and the desired success, which lies in the fact that new synthetically produced Vpr peptides are now available stand.
- the synthetic peptides produced according to the invention are distinguished by the following properties:
- the peptides can be produced under economically acceptable conditions on a mg scale and enriched to a high degree of purity. They show immunogenic and biological properties which are identical to those of natural Vpr proteins. They can be used for diverse areas of basic research as well as applied research in the field of HIV virology.
- the peptides according to the invention are used in biological assays, in the structural analysis of Vpr and its domains, for the generation of antibodies against HIV peptide sequences, in antiviral reagents, for the construction of test systems for the screening of potential Vpr antagonists, in the establishment of cell culture and Animal models, for the investigation of the pathomechanisms of Vpr, for the in vitro assembly of novel vectors for use in gene transfer methods in gene therapy and for the development of serological test methods, in particular a Vpr antigen ELISA.
- the products produced according to the invention can be used for the elucidation of the molecular structure of Vpr by means of NMR and CD spectroscopic methods as well as for crystallization and subsequent RKSA.
- Vpr protein in the HIV-1 replication cycle and the associated pathomechanisms of an AIDS disease, as well as the molecular design of potential Vpr antagonists.
- these products can be used to display in vitro test systems which allow the intensive screening of potential anti-Vpr-active reagents.
- they can be used for the generation and testing of Vpr-specific antibodies and for serological test procedures.
- the invention is in peptide chemistry. basic virological research, structural analysis and medical diagnostics.
- the invention can be used for the production of poly- and monoclonal Vpr-specific antibodies or antisera, especially for the production of epitope-different Vpr-specific antibodies.
- serological test methods as Vpr antigen (Ag) ELISA, as standard antigen for the calibration of Vpr-Ag ELISA techniques, detection for determining the concentration of viral Vpr in the blood of HIV-infected individuals, test systems for the determination of Vpr antagonists, complementing the function of endogenous viral Vpr in cell cultures infected with vpr-deficient HIV mutants, complementing the function of viral Vpr in cultures of primary human lymphocytes infected with vpr-deficient HIV mutants and Complementing the function of viral Vpr in cultures of differentiated primary human monocytes / macrophages infected with vpr-deficient HIV mutants.
- the invention is also useful for determining reagents that a) prevent Vpr from interacting with cellular factors such as the glucocorticoid receptor, transcription factors and other DNA interacting enzymes and factors; b) prevent the transcription activating effect of Vpr; regulate, influence or prevent the activity of Vpr on the effects of steroid hormones; c) regulate, influence or prevent the transport of Vpr alone or in combination with other components of the HIV pre-integration complex; regulate, influence or prevent the incorporation of Vpr into virus particles during HIV assembly; d) regulate, influence or prevent the effect of Vpr on cell differentiation and cell growth, regulate, influence or prevent the Vpr-induced cell cycle arrest e) regulate, influence or prevent the cytotoxic effects of Vpr and f) regulate, influence or prevent the ion channel activity of Vpr
- Vpr antagonists It is also used for in vivo test systems for the determination of Vpr antagonists possible.
- the invention is also suitable for animal model studies. Another advantage is that concentrated peptide solutions can be provided. In this way specific Vpr antagonists can be produced.
- Another area of application is the reduction of the flexibility of sVpr protein induced by the N-terminal domain of Vpr by means of structure-stabilizing factors. These factors are the UBA2 domain of the DNA repair protein HHR23A. which binds to Vpr, Fab fragments of Vpr-specific immunoglobulins or viral factors, in particular components of the HIV-1 Gag polyprotein precursor Pr55Gag, which in the process of virus assembly come into contact with Vpr, the human glucocorticoid receptor or components thereof.
- an in vitro assembly of retroviral pre-integration complexes in vitro or in vivo applicable gene transfer methods, transfections, integration into chromosomal and episomal host DNA or other gene transfer methods in eukaryotic cells or gene transfers of in vitro produced and / or manipulated gene fragments in cells , Tissues or organisms for the purpose of gene therapy application.
- Vpr peptides were synthesized on a serine resin from Rapp Polymer Tübingen on an ABI 433 A synthesizer (Perkin Elmer).
- N-terminal peptides were synthesized on a polystyrene-polyoxyethylene carrier resin (TentaGel R-RAM resin from Rapp Polymer).
- the peptides were built up using FMOC (fluoromethyloxycarbonyl) strategy using the following protective groups: Ot.Butyl ester for Glu and Asp, OtBu ether for serine. Tyrosine and threonine. Boc (tert-butoxycarbonyl-) for lysine and tryptophan.
- Trt (trityl - triphenylmethyl-) for histidine, glutamine and asparagine and Pbf (2.2.4.6.7-pentamethyl-dihydrobenzofuran-5-sulfonyl-) for arginine.
- the protective groups were cleaved off using a cleavage mixture consisting of 95% trifluoroacetic acid. the 3% triisopropylsilane and, depending on the peptide, 2 to 5% ethanedithiol was added. The resin was separated off, the reaction solution was concentrated and heptane was added. It was concentrated again and the remaining oil was digested with diethyl ether. The crude peptide was suctioned off and then lyophilized from 10% acetic acid.
- the peptide was constructed on a TentaGel S-AC resin (0.20 mmol / gram) on an ABI 433. At the end of the synthesis, the FMOC protective group was split off, the resin was washed successively with dimethylformamide and methylene chloride and dried. The peptide was then cleaved from the resin in the manner described at the outset and then purified.
- Molar mass 11378 found 11381 H-Met-Glu-Gln-Ala-Pro-Glu-Asp-Gln-Gly-Pro-Gln-Arg-Glu-Pro-Tyr-Asn-Glu-T ⁇ -Thr-Leu- Glu-Leu-Leu-Glu -Glu-Leu-Lys-Ser-Glu-Ala-Val-Arg-His-Phe-Pro-Arg-Ile-T ⁇ -Leu-His-Asn-Leu-Gly-Gln-His-Ile-Tyr-Glu-Thr -Tyr-Gly-Asp-Thr-T ⁇ -Ala-Gly-Val-Glu-Ala-Ile-Ile-Arg-Ile-Leu-Gln-Gln-Leu-leu-Phe-Ile-His-Phe-Arg-Ile -Gly-Cys-Arg-His-Ser-Arg-Ile-Gly-Val-Thr-
- Example 4 sVprl-47 Analogous to Examples 1 to 3. Molar mass: 5728 found. 5728.8
- Example 5 sVpr48-96 Analogous to Examples 1 to 3.
- Example 7 sVprl-20 (Asn ? '10 14 ) Analogous to Examples 1 to 3.
- Example 8 sVpr21-40 Analogous to Examples 1 to 3. Wild-type sequence H-Glu-Leu-Leu-Glu-Glu-Leu-Lys-Ser-Glu-Ala-Val-Arg-His-Phe-Asn-Arg- Ile-T ⁇ -Leu-His-NH 2
- a C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration. mitochondrial dysfunction and apoptosis of human CD4 + lymphocytes. Apoptosis 2: 69-76.
- LXX leucine triplet repeat sequence 4 in p6 g ⁇ g is important for Vpr inco ⁇ oration into human immunodeficiency virus type 1 particles. J. Virol. 69: 6873-6879.
- Vpr human immunodeficiency virus type 1
- Vpr function oligomerization by the N-terminal domain.
- Vpr amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino acid sequence of the amino
- Associated protein Vpr of HIV-1NL4-3 negatively charged N-terminus (marker (1), positions 1-17); Helix alpha- 1 (marker (2). Positions 18-37); an unspecified region (marker (3), positions 38-51); Helix alpha-2 (marker (4), positions 51-76); basic C-terminus (marker (8), positions 77-96). Overlapping, further areas are shown: a region rich in leucine and isoleucine, which is also referred to as a leucine zipper-like or "LR domain" (marker (5), positions 60-80); a region containing the repeating motif " ⁇ F / SRIG" (marker (6). positions 71-82); the presumed transmembrane anchor of Vpr, which is necessary for the ion channel activity of Vpr (marker (7), positions 52-79).
- Figure 2 Immunological reactivity of polyclonal antibodies specifically for sVprl-96 in western emblot and immunoprecipitation
- the autoradiogram of a 2-day exposure is shown in (A) and (B).
- the positions of standard molecular weight proteins are shown on the left, and the positions of non-specific reaction with the heavy (hc) and light chain (lc) of the immunoglobulins used for immunoprecipitation are shown on the right.
- FIG. 3 sVprl-96 activates virus replication and increases the number of living cells in cultures of human PBMC Cultures of PHA- and IL-2-activated PBMCs were infected with the same infectious doses of the following virus stocks: HIV-1NL4-3 (ABC), NL4-3 (AD8) (D) and the v-deficient mutant NL (AD8) -UDEL1 (E) and the vpr-deficient mutant NL (AD8) deltaR (F).
- the cultures were cultured in the presence of 10 nM sVprl-96 or 10 nM of the control peptide Vpu32-81.
- the virus release is shown as a profile of the virus-associated RT activity in the cell culture supernatant (A, C, D, E, F).
- (B) shows the number of living cells in the experiment of (A).
- Figure 4 s Vpr 1-96 activates the replication competence of vpr-deficient HIV-1 mutants in cultures of primary human monocytes / Mak ⁇ . phage isolated from different donors Parallel cultures of differentiated MDM isolates, from three different donors, were infected with the same infectious doses of purified viral stocks of the macrophage-tropic virus NL4-3 (AD8) and its vpr-deficient mutant NL (AD8) deltaR . Virus production was monitored over a period of about two months and plotted against time as virus-associated RT activity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000599775A JP2002540768A (ja) | 1999-02-19 | 2000-02-19 | ヒト免疫不全ウイルス1型(HIV−1)ウイルス性調節タンパク質R(Vpr)の合成ペプチドおよびその適用 |
EP00918674A EP1155035A2 (de) | 1999-02-19 | 2000-02-19 | Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung |
US09/913,927 US6984486B1 (en) | 1999-02-19 | 2000-02-19 | Synthetic peptide of regulatory virus protein R (VPR) of human immunodeficiency virus type 1 (HIV-1) and the utilization thereof |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19908766.0 | 1999-02-19 | ||
DE19908752A DE19908752A1 (de) | 1999-02-19 | 1999-02-19 | Synthetische Peptide des regulatorischen Virusproteins R (Vpr) des Humanen Immundefizienzvirus Typ 1 |
DE19908752.0 | 1999-02-19 | ||
DE19908766A DE19908766C2 (de) | 1999-02-19 | 1999-02-19 | Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien |
CA002356390A CA2356390A1 (en) | 1999-02-19 | 2001-08-17 | Synthetic peptide of regulatory virus protein r (vpr) of human immunodeficiency virus type 1 (hiv-1) and the utilization thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000049038A2 true WO2000049038A2 (de) | 2000-08-24 |
WO2000049038A3 WO2000049038A3 (de) | 2001-03-01 |
WO2000049038A9 WO2000049038A9 (de) | 2001-05-17 |
Family
ID=27808200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2000/000525 WO2000049038A2 (de) | 1999-02-19 | 2000-02-19 | Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1155035A2 (de) |
JP (1) | JP2002540768A (de) |
CA (1) | CA2356390A1 (de) |
WO (1) | WO2000049038A2 (de) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001090159A2 (en) * | 2000-05-23 | 2001-11-29 | The J. David Gladstone Institutes | Compositions and methods for delivery of a molecule into a cell |
WO2003089472A2 (en) * | 2002-04-22 | 2003-10-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anti-nls scfv and peptides and uses thereof in nuclear import inhibition |
WO2005030238A1 (fr) * | 2003-09-25 | 2005-04-07 | Theraptosis | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique |
WO2005103654A2 (fr) * | 2004-04-09 | 2005-11-03 | Bioalliance Pharma | Methode d’identification de composes actifs sur la replication du virus hiv. |
WO2006041192A1 (ja) * | 2004-10-12 | 2006-04-20 | Riken | アポトーシス誘導物質を含む医薬組成物 |
WO2007104932A2 (en) * | 2006-03-10 | 2007-09-20 | Peptcell Limited | Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4769009B2 (ja) * | 2005-04-05 | 2011-09-07 | オリエンタル酵母工業株式会社 | Vpr特異的モノクローナル抗体を産生するハイブリドーマを作製するためのVpr抗原、抗Vpr特異的モノクローナル抗体産生ハイブリドーマとそのハイブリドーマの産生する抗Vpr特異的モノクローナル抗体およびそれを利用したVprの免疫学的測定 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026361A1 (en) | 1994-03-25 | 1995-10-05 | Biomolecular Research Institute Ltd. | Vpr AND Vpx PROTEINS OF HIV |
WO1996007741A1 (en) | 1994-09-07 | 1996-03-14 | Universite De Montreal | Protein targeting into hiv virions based on hiv-1 vpr fusion molecules |
WO1996008970A1 (en) | 1994-09-21 | 1996-03-28 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR THE ABROGATION OF CELLULAR PROLIFERATION UTILIZING THE HUMAN IMMUNODEFICIENCY VIRUS Vpr PROTEIN |
US5580739A (en) | 1986-01-22 | 1996-12-03 | Institut Pasteur | Peptides of human immunodeficiency virus type 2 (HIV-2) and in vitro diagnostic methods and kits employing the peptides for the detection of HIV-2 |
US5639619A (en) | 1994-10-13 | 1997-06-17 | Regents Of The University Of California | Screening assay for anti-HIV drugs using the Vpr gene |
US5780238A (en) | 1993-12-15 | 1998-07-14 | The Trustees Of The University Of Pennsylvania | VPR receptor protein |
WO1998044945A1 (en) | 1997-04-04 | 1998-10-15 | The Immune Response Corporation | Non-infectious, protease defective hiv particles and nucleic acid molecules encoding therefor |
-
2000
- 2000-02-19 EP EP00918674A patent/EP1155035A2/de not_active Withdrawn
- 2000-02-19 WO PCT/DE2000/000525 patent/WO2000049038A2/de active Application Filing
- 2000-02-19 JP JP2000599775A patent/JP2002540768A/ja active Pending
-
2001
- 2001-08-17 CA CA002356390A patent/CA2356390A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5580739A (en) | 1986-01-22 | 1996-12-03 | Institut Pasteur | Peptides of human immunodeficiency virus type 2 (HIV-2) and in vitro diagnostic methods and kits employing the peptides for the detection of HIV-2 |
US5780238A (en) | 1993-12-15 | 1998-07-14 | The Trustees Of The University Of Pennsylvania | VPR receptor protein |
WO1995026361A1 (en) | 1994-03-25 | 1995-10-05 | Biomolecular Research Institute Ltd. | Vpr AND Vpx PROTEINS OF HIV |
WO1996007741A1 (en) | 1994-09-07 | 1996-03-14 | Universite De Montreal | Protein targeting into hiv virions based on hiv-1 vpr fusion molecules |
WO1996008970A1 (en) | 1994-09-21 | 1996-03-28 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR THE ABROGATION OF CELLULAR PROLIFERATION UTILIZING THE HUMAN IMMUNODEFICIENCY VIRUS Vpr PROTEIN |
US5639619A (en) | 1994-10-13 | 1997-06-17 | Regents Of The University Of California | Screening assay for anti-HIV drugs using the Vpr gene |
US5721104A (en) | 1994-10-13 | 1998-02-24 | Regents Of The University Of California | Screening assay for anti-HIV drugs |
WO1998044945A1 (en) | 1997-04-04 | 1998-10-15 | The Immune Response Corporation | Non-infectious, protease defective hiv particles and nucleic acid molecules encoding therefor |
Non-Patent Citations (2)
Title |
---|
W. SCHULER ET AL.: "NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: Molecular insights into its biological functions", JOURNAL OF MOLECULAR BIOLOGY, vol. 285, no. 5, 5 February 1999 (1999-02-05), pages 2105 - 2117 |
Z. LUO ET AL.: "Structural Studies of Synthetic Peptide Fragments derived from the HIV-1 Vpr Protein", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 244, no. 3, 27 March 1998 (1998-03-27), pages 732 - 736 |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001090159A2 (en) * | 2000-05-23 | 2001-11-29 | The J. David Gladstone Institutes | Compositions and methods for delivery of a molecule into a cell |
WO2001090159A3 (en) * | 2000-05-23 | 2002-06-13 | David Gladstone Inst | Compositions and methods for delivery of a molecule into a cell |
US6664040B2 (en) | 2000-05-23 | 2003-12-16 | The Regents Of The University Of California | Compositions and methods for delivery of a molecule into a cell |
WO2003089472A2 (en) * | 2002-04-22 | 2003-10-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Anti-nls scfv and peptides and uses thereof in nuclear import inhibition |
WO2003089472A3 (en) * | 2002-04-22 | 2004-05-13 | Yissum Res Dev Co | Anti-nls scfv and peptides and uses thereof in nuclear import inhibition |
WO2005030238A1 (fr) * | 2003-09-25 | 2005-04-07 | Theraptosis | Peptides possedant notamment une activite anti-angiogenique et leurs applications en therapeutique |
WO2005103654A2 (fr) * | 2004-04-09 | 2005-11-03 | Bioalliance Pharma | Methode d’identification de composes actifs sur la replication du virus hiv. |
WO2005103654A3 (fr) * | 2004-04-09 | 2006-01-26 | Bioalliance Pharma | Methode d’identification de composes actifs sur la replication du virus hiv. |
WO2006041192A1 (ja) * | 2004-10-12 | 2006-04-20 | Riken | アポトーシス誘導物質を含む医薬組成物 |
WO2007104932A2 (en) * | 2006-03-10 | 2007-09-20 | Peptcell Limited | Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof |
WO2007104932A3 (en) * | 2006-03-10 | 2007-11-22 | Peptcell Ltd | Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof |
AU2007226430B2 (en) * | 2006-03-10 | 2013-08-29 | Peptcell Limited | Peptides of regulatory or accessory proteins of HIV, compositions and the utilization thereof |
EA019733B1 (ru) * | 2006-03-10 | 2014-05-30 | Пептселл Лимитед | Иммуногенный полипептид для лечения и/или профилактики вич-инфекции |
US8992934B2 (en) | 2006-03-10 | 2015-03-31 | Peptcell Limited | Peptide Sequences of HIV polypeptides and compositions thereof |
CN104558126A (zh) * | 2006-03-10 | 2015-04-29 | 派特塞尔有限公司 | Hiv的调节或辅助蛋白的肽、组合物及它们的应用 |
AP3642A (en) * | 2006-03-10 | 2016-03-16 | Peptcell Ltd | Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof |
US9675686B2 (en) | 2006-03-10 | 2017-06-13 | PepTCell, Ltd. | HIV peptides and immunogenic compositions |
US10034933B2 (en) * | 2006-03-10 | 2018-07-31 | PepTCell, Ltd. | HIV and immunogenic peptide sequences and compositions |
CN104558126B (zh) * | 2006-03-10 | 2020-02-14 | 派特塞尔有限公司 | Hiv的调节或辅助蛋白的肽、组合物及它们的应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2000049038A9 (de) | 2001-05-17 |
JP2002540768A (ja) | 2002-12-03 |
EP1155035A2 (de) | 2001-11-21 |
WO2000049038A3 (de) | 2001-03-01 |
CA2356390A1 (en) | 2003-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60215626T2 (de) | Antagonist für die multimerisierung von hiv-1 vif-protein | |
DE69434335T2 (de) | Synthetische peptidinhibitoren der hiv-übertragung | |
MILLER et al. | A structural correlation between lentivirus transmembrane proteins and natural cytolytic peptides | |
US5447915A (en) | Terminally blocked antiviral peptides | |
Jiang et al. | The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability | |
DD283935A5 (de) | Verfahren zur herstellung eines aids-virus-impfstoffes | |
DE69133242T2 (de) | Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus | |
AT398080B (de) | Immortalisierte zellinie, verfahren zu ihrer herstellung und verfahren zur herstellung von monoklonalen antikörpern sowie diagnoseverfahren und -mittel | |
DE69736474T2 (de) | Antikörper gegen einen komplex aus cd4 und einer chemokinrezeptordomäne, sowie deren verwendung gegen hiv infektionen | |
DE60015312T2 (de) | Anti-hiv-1 impfstoff enthaltend das ganzen hiv-1 tat protein oder ein teil davon | |
WO2000049038A2 (de) | Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung | |
US11680086B2 (en) | Lipopeptide for potently inhibiting HIV, derivative thereof, pharmaceutical composition thereof and use thereof | |
DE69132795T3 (de) | Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt | |
Secchi et al. | Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides | |
DE69233455T2 (de) | Modifizierte proteine und deren verwendung zur kontrolle von virusinfektionen | |
DE60221805T2 (de) | Peptide mit affinität zu gp120, und ihre verwendungen | |
EP1228203B1 (de) | Humanes zirkulierendes virus inhibierendes peptid (virip) und seine verwendung | |
EP0732339B1 (de) | Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung | |
WO1991018454A1 (en) | Compositions capable of blocking cytotoxicity of viral regulatory proteins and neurotoxic symptoms associated with retroviral infection | |
DE19908752A1 (de) | Synthetische Peptide des regulatorischen Virusproteins R (Vpr) des Humanen Immundefizienzvirus Typ 1 | |
DE69433057T2 (de) | Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus | |
US6984486B1 (en) | Synthetic peptide of regulatory virus protein R (VPR) of human immunodeficiency virus type 1 (HIV-1) and the utilization thereof | |
DE19908766C2 (de) | Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien | |
EP0981543A1 (de) | Verfahren zum nachweis von hiv-antikörpern und dazu verwendete antigene | |
EP1754715A1 (de) | Impfstoff auf Basis virusneutralisierender Antikörper |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 21-23, CLAIMS, REPLACED BY NEW PAGES 21-23; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 599775 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000918674 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000918674 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09913927 Country of ref document: US |